Sign inJoin waitlistJoin the waitlist

Muhammad Furqan

Physician · University of Oklahoma College of Medicine

Credentials: · · · · ·

History

University of Oklahoma College of Medicine
2025–Present

Hematology and Medical Oncology
2008–2011
Internal Medicine
Rutgers Health
2005–2008
Doctor of Medicine
2001–2005

Research

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Cancer Cell · 2017 · 321 citations
MEK and the inhibitors: from bench to bedside
Review · Journal of Hematology & Oncology · 2013 · 245 citations
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Nature Medicine · 2024 · 227 citations

Bryan Allen
14 papers
GC
Gerald Clamon
10 papers
TH
Taher Abu Hejleh
10 papers
Akintunde Akinleye
7 papers · 3 as a resident
DL
Delong Liu
7 papers
John Buatti
7 papers
JZ
Jun Zhang
6 papers
Varun Monga
6 papers · 2 as a fellow
John Keech
4 papers
Joseph Cullen
4 papers
NM
Nikhil Mukhi
4 papers · 4 as a fellow
Abdul Samdani
3 papers

Grants

A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
National Cancer Institute · UG1
Contact PI · $4.8M · University of Oklahoma Hlth Sciences Ctr
2019–2032
Stephenson Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $56.2K · University of Oklahoma Hlth Sciences Ctr
2018–2028
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $522.8K · University of Iowa
2000–2027

Clinical trials

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2027–2032
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Principal investigator · Recruiting · Phase 2
CellSight Technologies, Inc.
2023–2026
Test-retest Evaluation of [18F]F-AraG PET
Principal investigator · Recruiting · Phase 2
CellSight Technologies, Inc.
2023–2025
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
Muhammad Furqan
2021–2027